menu
Home
About Us
Company Overview
Our Team
Our Facilities
Our Platform
Immuno-Oncology Pipeline
Newsroom
Investor Relations
Investment Overview
Investor FAQ
IR Contacts
Presentations
Contact
中文
CBMG
News Room
Archive of CBMG official press releases
scroll
May 2, 2023
news
CBMG Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma
Oct 31, 2022
Technology
CBMG Announces FDA Clearance of IND Application for Novel TIL Therapy C-TIL051
Jan 12, 2022
Technology
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations
Dec 13, 2021
Technology
CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Sep 30, 2021
news
CBMG Holdings Completes $120 Million in Series A Funding
Feb 19, 2021
Events
Cellular Biomedicine Group, Inc. Announces Completion of Merger
PDF VERSION
Feb 8, 2021
Events
CBMG Stockholders Approve Merger
PDF VERSION
Jan 28, 2021
Events
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend CBMG Stockholders Vote FOR Proposed Merger
PDF VERSION
Dec 4, 2020
Events
CBMG Announces Data to be Presented at 2020 ASH Annual Meeting
PDF VERSION
Nov 9, 2020
Financial Reports
CBMG Reports Q3 2020 Financial Results and Business Highlights
PDF VERSION
Aug 26, 2020
Events
CBMG to Present at Chinese Biopharmaceutical Association-USA Annual Conference
Aug 12, 2020
Events
Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private
PDF VERSION
Aug 12, 2020
Financial Reports
CBMG Reports Q2, H1 2020 Financial Results and Business Highlights
PDF VERSION
Jul 13, 2020
Events
CBMG Hosts R&D Showcase and Provides Updates to Clinical Programs
PDF VERSION
Jun 30, 2020
Events
CBMG to Host Investor R&D Showcase Highlighting Updates to Clinical Programs
PDF VERSION
PREV
01
.......
15
NEXT